IL2 and graft versus host disease: Moreover, this strategy demonstrated no adverse off-target effects while preserving the GVL, thereby offering a promising new therapeutic avenue for enhancing the prognosis of recipients undergoing allo-HSCT [93].Blocking the binding of IL-2 to the IL-2 receptor on T cells through the administration of anti-IL-2 monoclonal antibodies (e.g., JES6) has proven effective in preventing GVHD while preserving robust GVL activity.